IBD Serology and Disease Outcomes in African Americans with Crohn's Disease
JournalInflammatory Bowel Diseases
PublisherOxford University Press
MetadataShow full item record
AbstractBackgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and severity among Northern Europeans (NE) with Crohn's disease (CD). However, very little is known about the role of serology in CD among African Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry. Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immunosorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery. Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4%), perianal disease (55.7%), and documented colonic inflammation (86.8%). On multivariable analysis, both IgG ASCA and OmpC were associated with complicated disease (OR, 2.67; 95% CI, 1.67-4.28; OR, 2.23; 95% CI, 1.41-3.53, respectively) and disease requiring surgery (OR, 2.51; 95% CI, 1.49-4.22; OR, 3.57; 95% CI, 2.12-6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome. Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies equally to AA populations. Copyright 2017 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved.
SponsorsSupported by NIH/NIDDK R01 DK087694 (S.K.) and National Center for Advancing Translational Sciences of National Institute of Health Award Number UL1TR000454 (M.B.).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85051411573&doi=10.1093%2fibd%2fizx021&partnerID=40&md5=008371ce7ef9f8676fa9ee384ec63a64; http://hdl.handle.net/10713/9763
- Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
- Authors: Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A
- Issue date: 2004 Nov
- Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
- Authors: Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M
- Issue date: 2003 Dec
- Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease.
- Authors: Amcoff K, Joossens M, Pierik MJ, Jonkers D, Bohr J, Joossens S, Romberg-Camps M, Nyhlin N, Wickbom A, Rutgeerts PJ, Tysk C, Bodin L, Colombel JF, Vermeire S, Halfvarson J
- Issue date: 2016 Jun
- The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population.
- Authors: O'Donnell S, O'Sullivan M, O'Morain CA, Ryan BM
- Issue date: 2013 Dec
- Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.
- Authors: Forcione DG, Rosen MJ, Kisiel JB, Sands BE
- Issue date: 2004 Aug